Interact to see
Advertisement
Advertisement
ADNRX vs FSMAX
ADNRX vs FSMAX Comparison
Open Charts ADNRX vs FSMAX
American Beacon ARK Transfmt Innov R6
Price$19.51
Change+$0.39 (+2.04%)
VolumeN/A
Net Assets201.11M
Fidelity Extended Market Index
Price$92.17
Change+$1.25 (+1.37%)
VolumeN/A
Net Assets37.61B
ADNRX vs FSMAX Comparison Chart in %
Loading...
View a ticker or compare two or three
VS
VS
ADNRX vs. FSMAX commentary
Jun 27, 2025
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ADNRX is a Hold and FSMAX is a StrongBuy.
FUNDAMENTALS
Fundamentals
FSMAX has more cash in the bank: 37.6B vs. ADNRX (201M). FSMAX pays higher dividends than ADNRX: FSMAX (0.50) vs ADNRX (0.00). ADNRX was incepted earlier than FSMAX: ADNRX (5 years) vs FSMAX (14 years). ADNRX (1.13) is less costly to investors than FSMAX (0.04). ADNRX is a more actively managed with annual turnover of: 38.00 vs. FSMAX (9.00). ADNRX (0) and FSMAX (0) have matching initial minimum investment requirements. ADNRX annual gain was more profitable for investors over the last year : 63.13 vs. FSMAX (14.57).
| ADNRX | FSMAX | ADNRX / FSMAX | |
| Total Expense Ratio | 1.00 | 0.04 | 2,857% |
| Annual Report Gross Expense Ratio | 1.13 | 0.04 | 3,229% |
| Fund Existence | 5 years | 14 years | - |
| Gain YTD | 25.144 | 0.044 | 57,127% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 0 | 0 | - |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 201M | 37.6B | 1% |
| Annual Yield % from dividends | 0.00 | 0.50 | - |
| Returns for 1 year | 63.13 | 14.57 | 433% |
| Returns for 3 years | 47.47 | 43.69 | 109% |
| Returns for 5 years | N/A | 64.38 | - |
| Returns for 10 years | N/A | 73.79 | - |